ICER And The VA: Match Made in Heaven?
Institute for Clinical and Economic Review partners with the US Department of Veterans Affairs to support the agency's approach to negotiating and contracting for prescription drugs.
You may also be interested in...
Deal with Veterans Administration also expected; companies say they will work with payers to ‘address’ pricing if patient population and uptake for their Alzheimer's drug are greater than expected.
Amgen's FOURIER study prompts ICER to plan new value-based price benchmark for Repatha below its previously recommended range of $5,404 to $7,735 per year.
Draft report concludes that added cost of abuse-deterrent opioids is not outweighed by reductions to health care system costs resulting from their use.